Statement of Changes in Beneficial Ownership (4)
February 04 2022 - 06:38PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5
obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL
OWNERSHIP OF SECURITIES
|
OMB
APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5 |
|
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934 or Section 30(h) of the Investment
Company Act of 1940
|
|
1. Name
and Address of Reporting Person * McClurg Ronald
W. |
2. Issuer Name and Ticker or Trading
Symbol NEUROONE MEDICAL TECHNOLOGIES Corp [ NMTC
] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)_____
Director _____
10% Owner
__X__ Officer (give title
below) _____ Other
(specify below)
Chief Financial Officer |
(Last)
(First)
(Middle)
C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM
DR |
3. Date of Earliest Transaction (MM/DD/YYYY)
2/3/2022
|
(Street)
EDEN PRAIRIE, MN 55344
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or
Beneficially Owned
|
1.Title of Security
(Instr. 3) |
2. Trans. Date |
2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following
Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) |
7. Nature of Indirect Beneficial Ownership (Instr.
4) |
Code |
V |
Amount |
(A) or (D) |
Price |
Common Stock |
2/3/2022 |
|
A |
|
15000 (1) |
A |
$0 |
15000 |
D |
|
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible
securities)
|
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative
Security |
3. Trans. Date |
3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or
Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying
Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially
Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct
(D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr.
4) |
Code |
V |
(A) |
(D) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
Explanation of
Responses: |
(1) |
Represents a grant of
restricted stock units, which vest as to 50% of the shares on the
first anniversary of the grant date, with the remaining shares
vesting in equal monthly installments on the last day of each month
over the next 24 months, subject to continued service on such
vesting date. |
Reporting
Owners
|
Reporting Owner Name / Address |
Relationships
|
Director |
10% Owner |
Officer |
Other |
McClurg Ronald W.
C/O NEUROONE MEDICAL TECHNOLOGIES CORP
7599 ANAGRAM DR
EDEN PRAIRIE, MN 55344 |
|
|
Chief Financial Officer |
|
Signatures
|
/s/ Stephanie Swan, by Power of
Attorney |
|
2/4/2022 |
**Signature of
Reporting Person |
Date |
NeuroOne Medical Technol... (NASDAQ:NMTC)
Historical Stock Chart
From Jan 2023 to Feb 2023
NeuroOne Medical Technol... (NASDAQ:NMTC)
Historical Stock Chart
From Feb 2022 to Feb 2023